Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis

BACKGROUND: An increased lymphoma risk is well documented in systemic lupus (SLE). Less attention has been focused on women's cancers, even though SLE affects mostly females. Our objective was to estimate the risk of breast, ovarian, and endometrial cancers in SLE, relative to the general popul...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernatsky, S, Ramsey-Goldman, R, Foulkes, W D, Gordon, C, Clarke, A E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101932/
https://www.ncbi.nlm.nih.gov/pubmed/21487409
http://dx.doi.org/10.1038/bjc.2011.115
_version_ 1782204324451975168
author Bernatsky, S
Ramsey-Goldman, R
Foulkes, W D
Gordon, C
Clarke, A E
author_facet Bernatsky, S
Ramsey-Goldman, R
Foulkes, W D
Gordon, C
Clarke, A E
author_sort Bernatsky, S
collection PubMed
description BACKGROUND: An increased lymphoma risk is well documented in systemic lupus (SLE). Less attention has been focused on women's cancers, even though SLE affects mostly females. Our objective was to estimate the risk of breast, ovarian, and endometrial cancers in SLE, relative to the general population. METHODS: Data were included from five recent studies of large SLE cohorts. The number of cancers observed was determined for each cancer type. The expected number of malignancies was ascertained from general population data. The parameter of interest was the standardised incidence ratio (SIR), the ratio of observed to expected malignancies. RESULTS: The five studies included 47 325 SLE patients (42 171 females) observed for 282 553 patient years. There were 376 breast cancers, 66 endometrial cancers, and 44 ovarian cancers. The total number of cancers observed was less than that expected, with SIRs of 0.76 (95% CI: 0.69, 0.85) for breast cancer, 0.71 (95% CI: 0.55, 0.91) for endometrial cancer, and 0.66 (95% CI: 0.49, 0.90) for ovarian cancer. CONCLUSIONS: Data strongly support a decreased risk of breast, ovarian, and endometrial cancers in SLE. This may be due to inherent differences in women in SLE (vs the general population) regarding endogenous oestrogen, other medications, and/or genetic make-up.
format Text
id pubmed-3101932
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-31019322012-04-26 Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis Bernatsky, S Ramsey-Goldman, R Foulkes, W D Gordon, C Clarke, A E Br J Cancer Short Communication BACKGROUND: An increased lymphoma risk is well documented in systemic lupus (SLE). Less attention has been focused on women's cancers, even though SLE affects mostly females. Our objective was to estimate the risk of breast, ovarian, and endometrial cancers in SLE, relative to the general population. METHODS: Data were included from five recent studies of large SLE cohorts. The number of cancers observed was determined for each cancer type. The expected number of malignancies was ascertained from general population data. The parameter of interest was the standardised incidence ratio (SIR), the ratio of observed to expected malignancies. RESULTS: The five studies included 47 325 SLE patients (42 171 females) observed for 282 553 patient years. There were 376 breast cancers, 66 endometrial cancers, and 44 ovarian cancers. The total number of cancers observed was less than that expected, with SIRs of 0.76 (95% CI: 0.69, 0.85) for breast cancer, 0.71 (95% CI: 0.55, 0.91) for endometrial cancer, and 0.66 (95% CI: 0.49, 0.90) for ovarian cancer. CONCLUSIONS: Data strongly support a decreased risk of breast, ovarian, and endometrial cancers in SLE. This may be due to inherent differences in women in SLE (vs the general population) regarding endogenous oestrogen, other medications, and/or genetic make-up. Nature Publishing Group 2011-04-26 2011-04-12 /pmc/articles/PMC3101932/ /pubmed/21487409 http://dx.doi.org/10.1038/bjc.2011.115 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Bernatsky, S
Ramsey-Goldman, R
Foulkes, W D
Gordon, C
Clarke, A E
Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis
title Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis
title_full Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis
title_fullStr Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis
title_full_unstemmed Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis
title_short Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis
title_sort breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101932/
https://www.ncbi.nlm.nih.gov/pubmed/21487409
http://dx.doi.org/10.1038/bjc.2011.115
work_keys_str_mv AT bernatskys breastovarianandendometrialmalignanciesinsystemiclupuserythematosusametaanalysis
AT ramseygoldmanr breastovarianandendometrialmalignanciesinsystemiclupuserythematosusametaanalysis
AT foulkeswd breastovarianandendometrialmalignanciesinsystemiclupuserythematosusametaanalysis
AT gordonc breastovarianandendometrialmalignanciesinsystemiclupuserythematosusametaanalysis
AT clarkeae breastovarianandendometrialmalignanciesinsystemiclupuserythematosusametaanalysis